What is Atovaquone
Approved as Treatment by the FDAAtovaquone, otherwise called Mepron, is approved by the FDA for 2 uses which include Malaria and Malaria .
When to interrupt dosageThe measure of Atovaquone is contingent upon the pinpointed condition, such as prophylaxis of Pneumocystis jiroveci pneumonia, Genus Pneumocystis and Toxoplasmosis. The quantity of dosage alters as per the system of delivery (e.g. Tablet - Oral or Tablet, film coated - Oral) indicated in the table beneath.
WarningsThere are 20 known major drug interactions with Atovaquone.
Atovaquone Novel Uses: Which Conditions Have a Clinical Trial Featuring Atovaquone?124 active studies are presently examining the potential of Atovaquone for the management of Malaria, Babesiosis and HIV.
Atovaquone Reviews: What are patients saying about Atovaquone?
Patient Q&A Section about atovaquoneThese questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What type of antibiotic is atovaquone?
"Atovaquone is an antiprotozoal medication that works by preventing the growth of certain types of protozoa that can cause pneumonia."
Is atovaquone an antibiotic?
"Mepron is an antibiotic that is sold under different names in other parts of the world. It is used to fight infections caused by bacteria."
What is atovaquone used for?
"Atovaquone is used to prevent and treat Pneumocystis jiroveci pneumonia (PCP) in adults and children who cannot tolerate other medicines, such as trimethoprim-sulfamethoxazole. It can also be used to prevent PCP in adults and children 2 years of age and older with weakened immune systems who are at risk of getting this disease."
Does atovaquone treat Covid?
Atovaquone significantly inhibited viral replication compared with placebo (P=.02). Among patients treated with atovaquone, the time to viral clearance was significantly shorter than among those treated with placebo (P This trial provides evidence that atovaquone inhibits viral replication and may be a promising treatment for patients with COVID-19 infection.
These studies found that atovaquone could be a good treatment for inhibiting viral replication. A trial was done with patients who had COVID-19 infection, and it was found that atovaquone significantly inhibited viral replication compared to placebo. The time to viral clearance was also significantly shorter among patients treated with atovaquone. This provides evidence that atovaquone could be a promising treatment for patients with COVID-19 infection."